We examined the hypoxia score between non‐responders (NR), defined as progressive disease (PD), and responders, defined as partial/complete responders (PR/CR), in two skin cutaneous melanoma (SKCM) patient cohorts with anti‐PD‐1 treatment[32, 33] and a bladder cancer patient cohort with anti‐PD‐L1 treatment[34] observing that the hypoxia score is significantly lower in responders (Figure 1g). This evidence concerns the gene PDCD1 and cutaneous melanoma.